Editas Medicine Inc. (EDIT)
| Bid | 1.24 |
| Market Cap | 103.31M |
| Revenue (ttm) | 32.45M |
| Net Income (ttm) | -238.13M |
| EPS (ttm) | -2.95 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.98 |
| Analyst | Hold |
| Ask | 1.3 |
| Volume | 1,051,830 |
| Avg. Volume (20D) | 3,914,828 |
| Open | 1.31 |
| Previous Close | 1.30 |
| Day's Range | 1.24 - 1.31 |
| 52-Week Range | 1.12 - 7.41 |
| Beta | 1.87 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
Analyst Forecast
According to 14 analyst ratings, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 502.41% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Editas And Intellia: Strategic Shifts And Long-Term Investment PotentialIntellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despi...
